Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
Acute myeloid leukaemia
CD DiNardo, HP Erba, SD Freeman, AH Wei - The Lancet, 2023 - thelancet.com
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …
past decade has witnessed an increasingly improved scientific understanding of the …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
[HTML][HTML] The clinical impact of the molecular landscape of acute myeloid leukemia
S Kayser, MJ Levis - Haematologica, 2023 - ncbi.nlm.nih.gov
Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
led to remarkable advances in our understanding of the disease. Mutations now allow us to …
How I treat AML incorporating the updated classifications and guidelines
F El Chaer, CS Hourigan… - Blood, The Journal of the …, 2023 - ashpublications.org
Abstract The European LeukemiaNet recently revised both the clinical (2022) and
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …
measurable residual disease testing (2021) guidelines for acute myeloid leukemia (AML) …
[HTML][HTML] Moving toward individualized target-based therapies in acute myeloid leukemia
A Bazinet, HM Kantarjian - Annals of Oncology, 2023 - Elsevier
Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
[HTML][HTML] New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
The treatment of acute myeloid leukemia (AML) has evolved over the past few years with the
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
advent of next-generation sequencing. Targeted therapies alone or in combination with low …
Targeting FLT3 mutation in acute myeloid leukemia: current strategies and future directions
K Fedorov, A Maiti, M Konopleva - Cancers, 2023 - mdpi.com
Simple Summary FLT3 mutation is commonly present in newly diagnosed patients with
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …
An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape
R Bystrom, MJ Levis - Current oncology reports, 2023 - Springer
Abstract Purpose of Review This review aims to summarize the pathophysiology, clinical
presentation, and management of acute myeloid leukemia (AML) with FMS-like tyrosine …
presentation, and management of acute myeloid leukemia (AML) with FMS-like tyrosine …
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Abstract Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of
patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for …
patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for …